FDA Adverse Event Injury Summary report: N

COREVALVE TRANSCATHETER AORTIC VALVE

MDR report key: 6962527 · Received October 19, 2017

Report

Report Number
2025587-2017-01877
Event Type
Injury
Date Received
October 19, 2017
Date of Event
October 11, 2016
Report Date
October 19, 2017
Manufacturer
MEDTRONIC HEART VALVES DIVISION
Product Code
NPT
PMA / PMN Number
P130021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

CITATION: MARTINE GILARD. LATE OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS: THE FRANCE-2 REGISTRY. J AM COLL CARDIOL. 2016 OCT 11;68(15):1637-1647. DOI: 10.1016/J.JACC.2016.07.747 EARLIEST DATE OF PUBLISH USED FOR EVENT DATE. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REGARDING LATE OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR). ALL DATA WERE COLLECTED FROM MULTIPLE CENTERS BETWEEN 2010 AND 2012. THE STUDY POPULATION INCLUDED 4,201 PATIENTS (PREDOMINANTLY MALE; MEAN AGE 83 YEARS), 1,413 OF WHICH WERE IMPLANTED WITH MEDTRONIC COREVALVE (SERIAL NUMBERS NOT PROVIDED). AMONG ALL PATIENTS ADVERSE EVENTS INCLUDED: PERIPROSTHETIC AORTIC REGURGITATION, PERMANENT PACEMAKER IMPLANT, STROKE, MYOCARDIAL INFARCTION, ENDOCARDITIS, VASCULAR COMPLICATIONS AND BLEEDING. MULTIPLE MANUFACTURERS WERE NOTED IN THE LITERATURE; BASED ON THE AVAILABLE INFORMATION A DIRECT CORRELATION COULD NOT BE MADE BETWEEN THE OBSERVED ADVERSE EVENTS AND MEDTRONIC PRODUCT. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
740240 COREVALVE TRANSCATHETER AORTIC VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT MEDTRONIC HEART VALVES DIVISION CRS

Patients

Seq Age Sex Outcome Treatment
1 83 YR Required Intervention